文献速递炎症性肠病消化内镜

腹腔镜回盲部切除术与英夫利西单抗治疗克罗恩病末端回肠炎的成本效果:LIR!C试验

Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial.
PubMed 文献 · Gut · 2019-02-01

多中心随机对照试验纳入143例常规治疗失败的回盲部克罗恩病患者,比较腹腔镜回盲部切除术与英夫利西单抗的成本效果。术后1年切除组直接医疗成本低于英夫利西单抗组,平均差为€-8931(95%CI €-12 087至€-5097)。在WTP为€0/QALY时,切除组具有成本效果的概率为0.96,结论认为腹腔镜回盲部切除术是更具成本效果的选项。

核心结论

  • 与英夫利西单抗相比,腹腔镜回盲部切除术是具成本效果的治疗选择。

研究设计与样本

  • 在荷兰和英国的29个中心进行的多中心随机对照试验,纳入143例常规免疫调节剂或激素治疗>3个月失败且无关键性狭窄征象的末端回肠克罗恩病成人患者。
  • 随机分配至腹腔镜回盲部切除术或英夫利西单抗组,按意向性分析原则,采用多重插补处理缺失的成本和效果数据。

主要发现

  • 1年时切除组患者平均克罗恩病直接医疗总成本低于英夫利西单抗组(平均差€-8931;95%CI €-12 087至€-5097)。
  • 切除组总社会成本低于英夫利西单抗组,但差异无统计学意义(平均差€-5729,95%CI €-10 606至€172)。
  • 在WTP为€0/QALY获得时,切除组相比英夫利西单抗具成本效果的概率为0.96;在WTP为€20 000/QALY获得时升至0.98。
  • 在WTP为€0/IBDQ评分改善1分时,切除组具成本效果的概率为0.96;在WTP为€500/IBDQ评分改善1分时升至0.99。

临床怎么用

  • 对于常规治疗失败的末端回肠克罗恩病患者,腹腔镜回盲部切除术可作为与英夫利西单抗相比具成本效果的治疗选项。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evaluate the cost-effectiveness of laparoscopic ileocaecal resection compared with infliximab in patients with ileocaecal Crohn's disease failing conventional therapy. DESIGN: A multicentre randomised controlled trial was performed in 29 centres in The Netherlands and the UK. Adult patients with Crohn's disease of the terminal ileum who failed >3 months of conventional immunomodulators or steroids without signs of critical strictures were randomised to laparoscopic ileocaecal resection or infliximab. Outcome measures included quality-adjusted life-years (QALYs) based on the EuroQol (EQ) 5D-3L Questionnaire and the Inflammatory Bowel Disease Questionnaire (IBDQ). Costs were measured from a societal perspective. Analyses were performed according to the intention-to-treat principle. Missing cost and effect data were imputed using multiple imputation. Cost-effectiveness planes and cost-effectiveness acceptability curves were estimated to show uncertainty. RESULTS: In total, 143 patients were randomised. Mean Crohn's disease total direct healthcare costs per patient at 1 year were lower in the resection group compared with the infliximab group (mean difference €-8931; 95% CI €-12 087 to €-5097). Total societal costs in the resection group were lower than in the infliximab group, however not statistically significant (mean difference €-5729, 95% CI €-10 606 to €172). The probability of resection being cost-effective compared with infliximab was 0.96 at a willingness to pay (WTP) of €0 per QALY gained and per point improvement in IBDQ Score. This probability increased to 0.98 at a WTP of €20 000/QALY gained and 0.99 at a WTP of €500/point of improvement in IBDQ Score. CONCLUSION: Laparoscopic ileocaecal resection is a cost-effective treatment option compared with infliximab. CLINICAL TRIAL REGISTRATION NUMBER: Dutch Trial Registry NTR1150; EudraCT number 2007-005042-20 (closed on 14 October 2015).

来源:Gut,查看原文。版权归原作者所有。

引用

  1. de Groof EJ, Stevens TW, Eshuis EJ, et al. Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial. Gut. 2019. PMID: 31233395. doi:10.1136/gutjnl-2018-317539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。